Arthritis
We recommend
Reduction of Enthesitis in Patients with Psoriatic Arthritis Taking Tofacitinib
Inflammation in the area where a tendon, ligament, or joint capsule attaches to the bone occurs in 35–50% of patients with psoriatic arthritis (PsA). Its presence is associated with higher activity of PsA, and its intensity correlates with the degree of joint damage. Patients with enthesitis are generally in worse functional status and report greater fatigue, pain, and decreased productivity. How can treatment with tofacitinib affect this important domain of PsA?
Reduction of Inflammation in Vertebral Bodies and Posterolateral Structures of the Spine in Patients with Ankylosing Spondylitis Treated with Tofacitinib
A post hoc analysis of a phase II study with tofacitinib in patients with active ankylosing…
Discontinuation of Methotrexate After Initiation of Tofacitinib in the Treatment of Rheumatoid Arthritis
New real-world data show that in patients with rheumatoid arthritis (RA) who started treatment with…
Articles on this topic
EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May…
EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?
What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of…
Results of a 10-year follow-up on the safety and efficacy of etanercept treatment in patients with juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is defined as persistent arthritis of unknown etiology…
Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy
The authors of a newly published study sought to answer whether the risk of developing…
Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of…
Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment
An international team of experts evaluated the impact of cardiovascular (CV) risk on the…
Efficacy and Safety of Etanercept in the Therapy of Arthritis
A review by experts from Genoa, Italy, focused on the available knowledge regarding the…
Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study
Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the…
Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the…
Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)?…
Subscribe
E-courses on this topic
Most read on this topic
Journal on this topic
Related topic
Interesting links
E-courses on this topic
Most read on this topic
- Discontinuation of Methotrexate After Initiation of Tofacitinib in the Treatment of Rheumatoid Arthritis
- Changes in Intestinal Microflora Correlate with Disease Activity in Patients with Lupus Erythematosus
- Efficacy and Safety of Etanercept in the Therapy of Arthritis
- Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment
- Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
- Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?
Journal on this topic
Related topic
Interesting links